PT - JOURNAL ARTICLE AU - Lanskey, Juliette H AU - Kocagoncu, Ece AU - Quin, Andrew J AU - Cheng, Yun-Ju AU - Karadag, Melek AU - Pitt, Jemma AU - Isaac, John AU - Lowe, Stephen AU - Perkinton, Michael AU - Raymont, Vanessa AU - Singh, Krish D AU - Woolrich, Mark AU - Nobre, Anna C AU - Henson, Richard N AU - Rowe, James B AU - , TI - The New Therapeutics in Alzheimer’s Disease Longitudinal Cohort study (NTAD): study protocol AID - 10.1101/2021.05.18.21257340 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.18.21257340 4099 - http://medrxiv.org/content/early/2021/05/18/2021.05.18.21257340.short 4100 - http://medrxiv.org/content/early/2021/05/18/2021.05.18.21257340.full AB - Introduction With the pressing need to develop treatments that slow or stop the progression of Alzheimer’s disease, new tools are needed to reduce clinical trial duration and validate new targets for human therapeutics. Such tools could be derived from neurophysiological measurements of disease.Methods and Analysis The New Therapeutics in Alzheimer’s disease study (NTAD) aims to identify a biomarker set from magneto/electro-encephalographic that is sensitive to disease and progression over one year. The study will recruit 100 people with amyloid-positive mild cognitive impairment or early-stage Alzheimer’s disease and 30 healthy controls aged between 50 and 85 years. Repeat measurements of the clinical, cognitive and imaging data (magnetoencephalography, electroencephalography and magnetic resonance imaging) of participants with Alzheimer’s disease or mild cognitive impairment will be taken at baseline and at one year. To assess reliability of magneto/electro-encephalographic changes, a subset of 30 participants with mild cognitive impairment or early-stage Alzheimer’s disease will undergo repeat magneto/electro-encephalographic two weeks after baseline. Clinical and cognitive assessment will be repeated at 2 years. Linear mixed models of baseline and longitudinal change in neurophysiology are the primary analyses of interest, supported by Bayesian inference. Additional outputs will include relative effect sizes for physiological markers, atrophy and cognitive change and the respective numbers needed to treat each arm of simulated clinical trials of a future disease modifying therapy.Ethics and dissemination The study has received a favourable opinion from the East of England Cambridge Central Research Ethics Committee (REC reference 18/EE/0042). Results will be disseminated through internal reports, peer-reviewed scientific journals, conference presentations, website publication, submission to regulatory authorities and other publications. Data will be made available via the Dementias Platform UK Data Portal on completion of initial analyses by the NTAD study group.StrengthsNTAD is a longitudinal, multicentre study of magneto/electro-encephalographic measures of Alzheimer’s disease progressionNTAD assesses the test-retest reliability of magneto/electro-encephalographic parametersAll participants with early-stage Alzheimer’s disease or mild cognitive impairment will be amyloid-positiveLimitationsAttrition during follow up may limit inferencesRecruitment is from volunteer panels and clinical services that may not reflect national diversity of people affected by Alzheimer’s diseaseCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work is primarily supported by Dementias Platform UK (MR/L023784/1 & MR/L023784/2) and Alzheimer's Research UK (ARUK-PG2017B-19) with additional support from the Wellcome Trust (103838), Medical Research Council (SUAG/051 G101400; SUAG/046 G101400), NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) and NIHR Oxford Biomedical Research Centre (BRC-1215-20008). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has received a favourable opinion from the East of England Cambridge Central Research Ethics Committee (REC reference 18/EE/0042)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesImaging data and clinical severity scores are hosted by the Dementias Platform UK Imaging Platform (https://portal.dementiasplatform.uk), using XNAT technology (https://www.xnat.org). The data will be made available by a managed access process through the DPUK, subject to constraints to preserve confidentiality and privacy.